<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05020106</url>
  </required_header>
  <id_info>
    <org_study_id>Biomarker cut-off value</org_study_id>
    <nct_id>NCT05020106</nct_id>
  </id_info>
  <brief_title>The Diagnostic Cut-off Value of Core Biomarkers of Alzheimer's Disease</brief_title>
  <official_title>Study on the Diagnostic Cut-off Value of Core Biomarkers in Cerebrospinal Fluid and Blood of Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The participant in this study includes Alzheimer's disease (AD including familial AD and&#xD;
      sporadic AD) patients, amnestic mild cognitive impairment (aMCI) patients, non-AD dementia&#xD;
      patients and cognitively normal control.&#xD;
&#xD;
      The purpose of this study is to establish the best cut-off value of cerebrospinal fluid (CSF)&#xD;
      and blood β-amyloid (Aβ) 42/40, total tau (t-tau) , phosphorylated tau ,inflammatory factors,&#xD;
      etc. in diagnosis of Alzheimer's disease (AD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Incorporating patients who meet the criteria from Capital Medical University Xuanwu&#xD;
           Hospital including AD, aMCI, non-AD dementia and cognitively normal control.&#xD;
&#xD;
        2. Collect the information of clinical and neuropsychological assessment (mini-mental state&#xD;
           examination, MMSE, Montreal cognitive assessment, MoCA, and clinical dementia rating&#xD;
           scale, CDR), neuroimaging data including medial temporal atrophy (MTA) score, Fazekas&#xD;
           score, MRI, and PET(optional), as well as the biological sample, such as CSF and&#xD;
           peripheral blood.&#xD;
&#xD;
        3. To quantify levels of Aβ42, Aβ40, t-tau, p-tau, inflammatory factors, etc. in CSF and&#xD;
           blood.&#xD;
&#xD;
        4. Detect all participants ApoE genotype.&#xD;
&#xD;
        5. Independently establish the best cut-off value of Chinese people in our laboratory.&#xD;
&#xD;
        6. Analysis the relationships between core biomarkers in CSF/blood and ApoE genotype and&#xD;
           neuroimaging data.&#xD;
&#xD;
        7. Establish combined diagnostic model.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The cut-off value in diagnosing AD</measure>
    <time_frame>1 year</time_frame>
    <description>The best cut-off value of Aβ42, Aβ40, t-tau, p-tau, inflammatory factors, etc. in CSF and blood .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The receiver operating characteristic curve</measure>
    <time_frame>1 year</time_frame>
    <description>The receiver operating characteristic curve is used to show the relationship between sensitivity and specificity of core CSF and blood biomarkers in diagnosing AD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relationship between biomarker and clinical symptom</measure>
    <time_frame>1 year</time_frame>
    <description>The relationship is specifically expressed by relevance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The sensitivity</measure>
    <time_frame>1 year</time_frame>
    <description>The sensitivity is used to show the ability of core CSF and blood biomarkers to diagnose AD patients and is represented by true positive/ (true positive +false negative).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The specificity</measure>
    <time_frame>1 year</time_frame>
    <description>The specificity is used to show the ability of core CSF and blood biomarkers to avoid false AD patients and rule out AD patients and is represented by true negative/ (false positive + true negative).</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">3200</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Alzheimer's disease</arm_group_label>
    <description>Criteria for AD according to the 2011 NIA-AA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MCI group</arm_group_label>
    <description>aMCI diagnosed according to the criteria of 2004 Peterson.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-AD dementia</arm_group_label>
    <description>Frontotemporal dementia (FTD); or Parkinson's disease dementia (PDD); or dementia with Lewy bodies (DLB); or vascular dementia (VaD); or corticobasal degeneration (CBD); or dementia not otherwise specified.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cognitively normal controls</arm_group_label>
    <description>Individuals with normal cognitive function</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      cerebrospinal fluid,blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        AD patients (n=800); aMCI patients (n=800);non-AD dementia patients (n=800). cognitively&#xD;
        normal controls (n=800);&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 55-75. Written informed consent obtained from participant or legal guardian prior&#xD;
             to any study-related procedures. The diagnosis of AD is made using the National&#xD;
             Institute on Aging and the Alzheimer's Association (NIA-AA) criteria. The diagnosis of&#xD;
             aMCI is assigned according to 2004 Petersen criteria. As for non-AD dementia, the&#xD;
             McKeith criteria are used for DLB, the revised diagnostic criteria proposed by the&#xD;
             International bvFTD Criteria Consortium for behavioral variant FTD, the Gorno-Tempini&#xD;
             criteria for the semantic variant FTD or non-fluent aphasia, the Movement Disorder&#xD;
             Society Task Force criteria for PDD, the vascular behavioral and cognitive disorders&#xD;
             (Vas-Cog) criteria for VaD, the Armstrong's criteria for CBD, the CDC's diagnostic&#xD;
             criteria for CJD, etc. In addition, normal cognition is supported by MMSE, CDR and&#xD;
             other cognitive function scales.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other medical or psychiatric illness. No one can serve as an informant. Refused to&#xD;
             complete a cognitive test and provide biospecimen.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianping Jia, Doctor</last_name>
    <phone>8610-83199449</phone>
    <email>jiajp@vip.126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xuanwu Hospital of Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianping Jia, Doctor</last_name>
      <phone>8610-83199449</phone>
      <email>jiajp@vip.126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>July 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>September 13, 2022</last_update_submitted>
  <last_update_submitted_qc>September 13, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Jianping Jia</investigator_full_name>
    <investigator_title>Chief Director</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

